View in EDS PDF Full Text

Rituximab for secondary progressive multiple sclerosis: a case series.

Saved in:
Bibliographic Details
Title: Rituximab for secondary progressive multiple sclerosis: a case series.
Authors: Rommer PS (AUTHOR), Patejdl R (AUTHOR), Winkelmann A (AUTHOR), Benecke R (AUTHOR), Zettl UK (AUTHOR), Rommer, Paulus S (AUTHOR), Patejdl, Robert (AUTHOR), Winkelmann, Alexander (AUTHOR), Benecke, Reiner (AUTHOR), Zettl, Uwe K (AUTHOR)
Source: CNS Drugs. 2011, Vol. 25 Issue 7, p607-613. 7p.
Abstract: Background: While numerous substances have been developed for the treatment of relapsing-remitting multiple sclerosis over recent years, options are still limited for patients with secondary progressive multiple sclerosis (SPMS).Objectives and Methods: In this observational study we present clinical and CSF findings in three patients with SPMS who were treated with rituximab for at least 15 months.Results: During the observation period, no severe adverse effects occurred and the Expanded Disability Status Scale (EDSS) score stabilized in all patients after a dramatic increase over the previous years. In contrast to other publications, we showed that the time to reoccurrence of B cells was very variable and that serial CSF examinations in the course of treatment revealed a decline in intrathecal IgG synthesis.Conclusion: Rituximab seems to be effective in active SPMS. Restitution of the pathogenic immune response after administration of rituximab is variable. Further studies are needed to determine the optimal dosage and timing for rituximab therapy in multiple sclerosis. [ABSTRACT FROM AUTHOR]
Copyright of CNS Drugs is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 104650520
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Rituximab for secondary progressive multiple sclerosis: a case series.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Rommer+PS%22">Rommer PS</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Patejdl+R%22">Patejdl R</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Winkelmann+A%22">Winkelmann A</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Benecke+R%22">Benecke R</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Zettl+UK%22">Zettl UK</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Rommer%2C+Paulus+S%22">Rommer, Paulus S</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Patejdl%2C+Robert%22">Patejdl, Robert</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Winkelmann%2C+Alexander%22">Winkelmann, Alexander</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Benecke%2C+Reiner%22">Benecke, Reiner</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Zettl%2C+Uwe+K%22">Zettl, Uwe K</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22CNS+Drugs%22">CNS Drugs</searchLink>. 2011, Vol. 25 Issue 7, p607-613. 7p.
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: <bold>Background: </bold>While numerous substances have been developed for the treatment of relapsing-remitting multiple sclerosis over recent years, options are still limited for patients with secondary progressive multiple sclerosis (SPMS).<bold>Objectives and Methods: </bold>In this observational study we present clinical and CSF findings in three patients with SPMS who were treated with rituximab for at least 15 months.<bold>Results: </bold>During the observation period, no severe adverse effects occurred and the Expanded Disability Status Scale (EDSS) score stabilized in all patients after a dramatic increase over the previous years. In contrast to other publications, we showed that the time to reoccurrence of B cells was very variable and that serial CSF examinations in the course of treatment revealed a decline in intrathecal IgG synthesis.<bold>Conclusion: </bold>Rituximab seems to be effective in active SPMS. Restitution of the pathogenic immune response after administration of rituximab is variable. Further studies are needed to determine the optimal dosage and timing for rituximab therapy in multiple sclerosis. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of CNS Drugs is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=104650520
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.2165/11589390-000000000-00000
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 7
        StartPage: 607
    Titles:
      – TitleFull: Rituximab for secondary progressive multiple sclerosis: a case series.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Rommer PS
      – PersonEntity:
          Name:
            NameFull: Patejdl R
      – PersonEntity:
          Name:
            NameFull: Winkelmann A
      – PersonEntity:
          Name:
            NameFull: Benecke R
      – PersonEntity:
          Name:
            NameFull: Zettl UK
      – PersonEntity:
          Name:
            NameFull: Rommer, Paulus S
      – PersonEntity:
          Name:
            NameFull: Patejdl, Robert
      – PersonEntity:
          Name:
            NameFull: Winkelmann, Alexander
      – PersonEntity:
          Name:
            NameFull: Benecke, Reiner
      – PersonEntity:
          Name:
            NameFull: Zettl, Uwe K
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 07
              Text: 2011
              Type: published
              Y: 2011
          Identifiers:
            – Type: issn-print
              Value: 11727047
          Numbering:
            – Type: volume
              Value: 25
            – Type: issue
              Value: 7
          Titles:
            – TitleFull: CNS Drugs
              Type: main
ResultId 1